Endo International plc (NASDAQ: ENDP) Reports 12% YoY Drop in Q1 2021 Consolidated Revenue
Endo International plc (NASDAQ: ENDP) has reported its Q1 2021 financial results for the period ended March 31, 2021, in which consolidated revenue was $718 million, which is a 12% Yoy drop. The decline was a result of Sterile Injectable and Generic Pharmaceutical segment revenue decrease. Growing competition affected sales in Q1 2021 Branded pharmaceutical unit revenue was $207 million, with specialty product revenues jumping 7% to 143 million and…